BioRestorative Therapies (BioRestorative Therapies) Pre-Tax Income : $-14.42 Mil (TTM As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is BioRestorative Therapies Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. BioRestorative Therapies's pretax income for the three months ended in Dec. 2023 was $-2.83 Mil. Its pretax income for the trailing twelve months (TTM) ended in Dec. 2023 was $-14.42 Mil. BioRestorative Therapies's pretax margin was -14,868.42%.

During the past 13 years, BioRestorative Therapies's highest Pretax Margin was -1259.62%. The lowest was -96310.87%. And the median was -11468.99%.

BioRestorative Therapies Pre-Tax Income Historical Data

The historical data trend for BioRestorative Therapies's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioRestorative Therapies Pre-Tax Income Chart

BioRestorative Therapies Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Pre-Tax Income

Get a 7-Day Free Trial

-14.65

-11.27

-44.30

-18.50

-14.42

BioRestorative Therapies Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Pre-Tax Income	Get a 7-Day Free Trial															-4.35	-5.68	-2.98	-2.93	-2.83

Competitive Comparison of BioRestorative Therapies's Pre-Tax Income

For the Biotechnology subindustry, BioRestorative Therapies's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioRestorative Therapies's Pre-Tax Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioRestorative Therapies's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where BioRestorative Therapies's Pre-Tax Income falls into.

BioRestorative Therapies Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

BioRestorative Therapies's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-15.137	+	0.17	+	0	+	0.552	+	1.7763568394003E-15
	=	-14.42

BioRestorative Therapies's Pretax Income for the quarter that ended in Dec. 2023 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-3.221	+	0.019	+	0	+	0	+	0.377
	=	-2.83

Pre-Tax Income for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-14.42 Mil.

BioRestorative Therapies (NAS:BRTX) Pre-Tax Income Explanation

BioRestorative Therapies's Pretax Margin for the quarter that ended in Dec. 2023 is calculated as

Pretax Margin	=	Pretax Income	/	Revenue
	=	-2.825	/	0.019
	=	-14,868.42%

During the past 13 years, BioRestorative Therapies's highest Pretax Margin was -1259.62%. The lowest was -96310.87%. And the median was -11468.99%.

BioRestorative Therapies Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of BioRestorative Therapies's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.

BioRestorative Therapies (BioRestorative Therapies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioRestorative Therapies Inc (NAS:BRTX) » Definitions » Pre-Tax Income

Comparable Companies

Traded in Other Exchanges

9OF:Germany

Address

40 Marcus Drive, Suite One, Melville, NY, USA, 11747

Website

https://www.biorestorative.com

BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, primarily involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.

Executives

Dale Broadrick	10 percent owner	3003 BRICK CHURCH PIKE, NASHVILLE TN 37207
Lance Alstodt	director, 10 percent owner, officer: President, CEO, COB	BIORESTORATIVE THERAPIES, INC., 40 MARCUS DRIVE, SUITE 1, MELVILLE NY 11747
Francisco Silva	director, 10 percent owner, officer: VP of Research and Development	STEM CELL ASSURANCE, INC., 555 HERITAGE DRIVE, JUPITER FL 33458
Robert Eugene Kristal	officer: Chief Financial Officer	4719 COLE AVENUE, DALLAS TX 75205
Patrick F. Williams	director	C/O ZELTIQ AESTHETICS INC., 4698 WILLOW ROAD, SUITE 100, PLEASANTON CA 94588
David A Rosa	director	10901 RED CIRCLE DRIVE, SUITE 150, MINNETONKA MN 55343
Nickolay V. Kukekov	director	4524 WESTWAY AVE, DALLAS TX 75205
Mark Weinreb	director, 10 percent owner, officer: CEO and Chairman of the Board	STEM CELL ASSURANCE, INC., 555 HERITAGE DRIVE, JUPITER FL 33458
Paul Jude Tonna	director	69 CHICHESTER ROAD, HUNTINGTON NY 11743
A. Jeffrey Radov	director	8 WALWORTH AVENUE, SCARSDALE NY 10583
Robert Paccasassi	officer: VP, Quality and Compliance	C/O BIORESTORATIVE THERAPIES, INC., 40 MARCUS DRIVE, SUITE 1, MELVILLE NY 11747
Robert B Catell	director	62 OSBORNE ROAD, GARDEN CITY NY 11530
Adam D. Bergstein	officer: SVP, Planning and Business Dev	167 HAZEL AVENUE, GLENCOE IL 60022
John M Desmarais	director	230 PARK AVENUE, NEW YORK NY 10169
Westbury Trust	10 percent owner	VICTORIA HALL, 11 VICTORIA STREET, P.O. BOX HM 1065, HAMILTON D0 00000